19 results on '"Nakamura, Yoshiaki"'
Search Results
2. SY22-4 Current and future paradigms of liquid biopsy for cancer care.
3. DJS-3 Utilizing real-world data as an external control for new drug approval in molecular subtype: experience in SCRUM-Japan Registry.
4. AJS-3 Organ-specific and tumor-agnostic trials based on SCRUM-Japan MONSTAR-SCREEN.
5. MO1-15-3 Efficacy of Radiotherapy to Primary Tumor After Nivolumab Treatment in Patients with Advanced Gastric Cancer.
6. MO1-15-3 - Efficacy of Radiotherapy to Primary Tumor After Nivolumab Treatment in Patients with Advanced Gastric Cancer.
7. O1-21-3Predictive factor of hyperprogressive disease during nivolumab in patients with advanced gastric cancer.
8. O4-5 Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan.
9. MO42-6 The clinical and molecular landscape of focal MET-amplified metastatic colorectal cancer patients.
10. O2-1-3 - Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer.
11. O2-1-3 Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer.
12. MO1-19-2 Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer.
13. MO1-19-2 - Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer.
14. MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors.
15. O9-1 Updated analysis of circulating tumor DNA in advanced genitourinary cancers: SCRUM-Japan MONSTAR SCREEN Project.
16. O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN.
17. PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN.
18. MO1-15-2 Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer.
19. MO1-15-2 - Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.